Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 25 mg - polysorbat 80 hjälpämne; sitagliptinhydrokloridmonohydrat 27,238 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

avansor pharma oy - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 100 mg - sitagliptinhydrokloridmonohydrat 113,38 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

avansor pharma oy - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg - sitagliptinhydrokloridmonohydrat 56,69 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

as grindeks - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 25 mg - sitagliptinhydrokloridmonohydrat 28,35 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

as grindeks - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 100 mg - sitagliptinhydrokloridmonohydrat 113,4 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

as grindeks - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg - sitagliptinhydrokloridmonohydrat 56,7 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

zentiva k.s. - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 100 mg - sitagliptinhydrokloridmonohydrat 108,95 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

zentiva k.s. - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 25 mg - sitagliptinhydrokloridmonohydrat 27,238 mg aktiv substans; laktosmonohydrat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

zentiva k.s. - sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg - sitagliptinhydrokloridmonohydrat 54,475 mg aktiv substans